Crinetics Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

Checking your notes…

(In thousands, except per share data)

Revenue:
Product revenue, net	$5,420	$—	$—
Collaboration and license revenue	2,276	1,039	4,013
Total revenue, net	7,696	1,039	4,013
Operating expenses:
Cost of product revenue	1,076	—	—
Research and development	332,058	240,156	168,527
Selling, general and administrative	191,331	99,737	58,094
Total operating expenses	524,465	339,893	226,621
Loss from operations	(516,769)	(338,854)	(222,608)
Other income (expense):
Interest income	51,989	41,435	13,436
Other expense, net	(357)	(519)	(159)
Total other income, net	51,632	40,916	13,277
Loss before income taxes	(465,137)	(297,938)	(209,331)
Income tax expense	180	—	—
Loss before equity method investment	(465,317)	(297,938)	(209,331)
Loss on equity method investment	—	(470)	(5,198)
Net loss	$(465,317)	$(298,408)	$(214,529)
Net loss per share:
Net loss per share - basic and diluted	$(4.95)	$(3.69)	$(3.69)
Weighted average shares - basic and diluted	94,057	80,783	58,071
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	$1,074	$(14)	$4,908
Unrealized loss on foreign currency	(172)	—	—
Total other comprehensive income (loss)	902	(14)	4,908
Comprehensive loss	$(464,415)	$(298,422)	$(209,621)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.